Lugano, Switzerland – The ESMO Sarcoma and Rare Cancers Congress 2025, to be held from 20-22 March in Lugano, Switzerland, will be the convergence point for world-renowned experts to present and discuss developments in the diagnosis and treatment of rare solid tumours, going through their peculiar biology and molecular classification, while also addressing the methodological, organisational, and policy challenges that characterise this oncological area and its high unmet needs.
Participation will be onsite, with no virtual option available.
Programme picks
- The role of immunotherapy in the treatment of sarcomas, with a focus on neoadjuvant and adjuvant settings and discussions that lay the conceptual foundations for future trials.
- New insights into the global challenges and disparities in rare cancers’ clinical trials and care, and the potential of increased international collaboration, patient engagement, and telemedicine to overcome them.
- Challenges and opportunities in organising reference networks for rare cancers and the future of networking in the European Union.
- Novel data on the reported usefulness of high-quality real-world data as external comparator in clinical trials to demonstrate overall survival benefits compared to single-arm trials without external comparators.
- Related content: 61MO
- Results on new prognostic markers in rare endocrine tumours and an in-depth look at the specific issues in the management of patients with adrenal cancers.
- Insights on artificial intelligence in rare cancers: an added value for identifying radiation therapy and new targets, leveraging real-world data, and developing digital twins within the scope of precision medicine.
- Related content: Session on 22 March, 08:30 - 10:00 CET
The abstracts presented will be published online as a supplement to ESMO Open. The abstract titles can be viewed through the online programme.
Press accreditation
ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities and the embargo schedule for ESMO Sarcoma and Rare Cancers Congress 2025. To apply for press accreditation, please fill out the form available here. Please be kindly informed that onsite press accreditation will not be available.
Third Parties Media registration
Third Parties Media representatives and Filming Crews not eligible as press, must abide by the ESMO Policy on Media Activities Organised by Third Parties and can request a Third Parties Media badge through registration@esmo.org (Cc media@esmo.org).
Further information
ESMO Press Office
press@esmo.org
Notes to editors
Please make sure to use the official name of the meeting in your reports: ESMO Sarcoma and Rare Cancers Congress 2025 and the official congress hashtag #ESMOSarcomaAndRareCancers25. Follow it to stay up to date and use it to take part in the conversation on X (Twitter), LinkedIn, Facebook, Instagram, YouTube.